Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, has been making significant strides in the healthcare sector with its innovative approach to cancer treatment. The company’s primary focus is on developing and commercializing novel cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein, a critical component in the fight against cancer. This strategic focus positions Aprea Therapeutics at the forefront of cancer research, addressing a crucial need in oncology.
Operating within the health care sector, Aprea Therapeutics serves its customers in both the United States and Sweden, reflecting its international reach and commitment to addressing global health challenges. The company’s efforts are particularly noteworthy given the complexity and urgency of developing effective cancer treatments. By targeting the mutant p53 protein, Aprea Therapeutics is exploring a pathway that could potentially lead to breakthroughs in cancer therapy, offering hope to patients worldwide.
Financially, Aprea Therapeutics has experienced fluctuations typical of companies in the clinical stage of development. As of May 11, 2026, the company’s stock closed at $0.9 on the Nasdaq exchange. This figure represents a significant recovery from its 52-week low of $0.548, recorded on January 28, 2026. Despite these challenges, the company reached a 52-week high of $2.22 on July 22, 2025, indicating investor interest and confidence in its potential.
The company’s market capitalization stands at $11,150,000 USD, reflecting its current valuation in the market. However, the price-to-earnings ratio of -0.49 suggests that Aprea Therapeutics is not yet profitable, a common scenario for companies in the early stages of drug development. This financial metric underscores the high-risk, high-reward nature of the biopharmaceutical industry, where significant investments in research and development are necessary before achieving profitability.
Aprea Therapeutics’ commitment to innovation and its strategic focus on reactivating the mutant p53 protein highlight its potential to make a meaningful impact in the field of oncology. As the company continues its clinical trials and research efforts, it remains a key player in the healthcare sector, dedicated to advancing cancer treatment and improving patient outcomes. For more information about Aprea Therapeutics and its activities, interested parties can visit the company’s website at www.aprea.com .
